Tumores Mamários
Estudo randomizado | Duração da terapia adjuvante com inibidor de aromatase no câncer de mama pós-menopausa.
2 Ago, 2021 | 18:05h
Comentário no Twitter
In postmenopausal women with hormone-receptor-positive breast cancer who had 5 yrs of AI, extending adjuvant endocrine therapy by 5 years provides no benefit over a 2-year extension but is associated with a greater risk of bone fracturehttps://t.co/YDxeQVu8B9
— K Pavithran (@drkpavithran) July 29, 2021
Revisão sistemática | Reconstrução mamária após mastectomia.
22 Jul, 2021 | 12:56hBreast Reconstruction After Mastectomy – Agency for Healthcare Research and Quality
Impacto global do câncer atribuído ao consumo de álcool – “Em termos globais, estima-se que 741.300 casos, ou 4,1% de todos os novos casos de câncer em 2020, foram atribuídos ao consumo de álcool.”
14 Jul, 2021 | 11:36hComunicado de imprensa: Alcohol consumption linked to more than 740,000 new cancer cases in 2020 – The Lancet
Comentários: Alcohol caused 740,000 cancer cases globally last year – study – The Guardian E Expert reaction to study of alcohol and cancer – Science Media Centre
M-A | Gravidez após câncer de mama – “Estes resultados fornecem evidências sobre a segurança da concepção em sobreviventes de CA de mama.”
6 Jul, 2021 | 11:08hPregnancy After Breast Cancer: A Systematic Review and Meta-Analysis – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)
Comentário no Twitter
Honored and excited to share our large #metanalysis presented at #SABCS20 now published in @ASCO_pubs #JCO providing solid and reassuring evidence on fetal and maternal safety of #pregnancy after prior #BreastCancer history@OncoAlert #SurvOnc #bcsm
Link: https://t.co/lgKQDeB2VS pic.twitter.com/rTpFKsrpMc— Matteo Lambertini, MD PhD (@matteolambe) July 1, 2021
Estudo randomizado | Desfechos similares para o tratamento de 5 ou de 2 anos com zoledronato após quimioterapia adjuvante no câncer de mama inicial.
1 Jul, 2021 | 10:14hEstudo original: Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)
Estudo randomizado | Drogas protetoras cardíacas parecem ser desnecessárias para a maioria das pacientes com câncer de mama submetidas a tratamento adjuvante.
8 Jun, 2021 | 10:17hComentários: Heart-protecting drugs likely unnecessary for many breast cancer patients – American College of Cardiology